1. Retrospective evaluation of the safety of low-level laser therapy/photobiomodulation in patients with head/neck cancer. Science.gov (United States) Genot-Klastersky, M T; Paesmans, M; Ameye, L; Kayumba, A; Beauvois, S; Dragan, T; Van Gestel, D; Lalami, Y; Klastersky, J A 2019-09-09  PubMed DOI: 10.1007/s00520-019-05041-3  ISSN: 0941-4355 Keywords: Head/neck cancer, Laser therapy, Oral mucositis, Photobiomodulation, Prevention, Radiotherapy The standard therapeutic approach for locally advanced head and neck cancer is optimal use of radiation therapy with or without concomitant chemotherapy. The most common and distressing acute complication of such therapies is oral/pharyngeal mucositis that may be associated with severe morbidity and can interfere with the planned administration of therapy. We have identified all patients diagnosed with head/neck cancer between 2005 and 2009, having received radiotherapy with or without cisplatin-based chemotherapy. Radiotherapy consisted of intensity-modulated radiation therapy (IMRT) in all patients. In patients with grade > 2 mucositis, photobiomodulation (PBM) consisted of three sessions of low-level laser irradiation weekly, in accordance with recently published recommendations for PBM. Patients who did not receive PBM were those for whom that approach was not requested by the radiotherapists and those who declined it. Two hundred twenty-two patients (62%) received PBM and 139 did not (39%). The patient's characteristics were equally distributed between the two groups. For overall survival, time to local recurrence, and progression-free survival, there was no statistical evidence for a difference in prognosis between patients with and without PBM. In a multivariate analysis, after adjusting for known prognostic factors, we found no statistical evidence that PBM was related to overall survival, progression-free survival, or local recurrence. Our results show evidence of no effect of PBM upon overall survival, time to local recurrences, and disease-free survival of patients with head and neck cancer treated with radiotherapy with/without chemotherapy. 2. Complicações bucais da radioterapia em cabeça e pescoço  OpenAIRE (Portuguese) Jham,Bruno Correia; Freire,Addah Regina da Silva 2019-08-31 A radioterapia é uma forma terapêutica amplamente utilizada para o tratamento das neoplasias malignas da cabeça e pescoço. Porém, altas doses de radiação em extensos campos que irão incluir a cavidade bucal, maxila, mandíbula e glândulas salivares freqüentemente resultam em diversas reações indesejadas. Dentre as complicações da radioterapia estão a mucosite, candidose, disgeusia, cárie por radiação, osteorradionecrose, necrose do tecido mole e xerostomia. OBJETIVO: O objetivo deste artigo é fazer uma breve revisão das reações adversas que podem ser detectadas durante o tratamento radioterápico em região de cabeça e pescoço. MÉTODO: A literatura pertinente que trata do assunto foi revisada. FORMA DE ESTUDO: Revisão de literatura. RESULTADOS: A radioterapia ainda está associada a diversas reações adversas, que afetam de forma significativa a qualidade de vida dos pacientes. CONCLUSÕES: O tratamento multidisciplinar, incluindo a equipe médica, o cirurgião-dentista, o fonoaudiólogo, o nutricionista e o psicólogo é a melhor alternativa para minimizar ou mesmo prevenir tais complicações. 3. Head And Neck Rhabdomyosacroma In Childhood: An ...  African Journals Online (AJOL) 2009-02-01 Feb 1, 2009 ... Background: Rhabdomyosarcoma may be histologically indistinguishable from other undifferentiated childhood tumours occurring in the head and neck region ... 4. Risco de desnutrição em doentes com cancro da cabeça e pescoço OpenAIRE (Portuguese) Ana Gabriela Paupério Duarte Oliveira 2019-09-04 5. Head and Neck Cancer in Saudi Arabia: a Systematic Review  KoreaScience (Korea) Alhazzazi, Turki Y; Alghamdi, Faisal T 2016-01-01  Asian Pacific Journal of Cancer Prevention DOI: 10.14456/apjcp.2016.212/APJCP.2016.17.8.4043  Volume: 17  Issue: 8  Pages: 4043-4048 Full Text Available Background: Head and neck cancer (HNC) is the ninth most common cancer worldwide, and has a poor 5-year survival rate averaging 50%, which has not changed for decades. A high prevalence of HNC has been reported in the southwestern region of Saudi Arabia, as compared to other areas of the country. However, data in regards to HNC are scattered and not well documented. Thus, the aim of this systematic review was to gather all available and updated important information regarding HNC in Saudi Arabia, and highlight the gaps of knowledge in our country with regard to this disease. In addition, suggestions of solutions to overcome the current status and improve our future standard of care to fight HNC are also highlighted. Materials and Methods: The electronic databases PubMed and Google Scholar using English-language literature were used for this systematic review, using specific inclusion and exclusion criteria and keywords. The search was performed in April 2016 and updated in June 2016. Results: Our search revealed twenty-one studies that fulfilled our inclusion and exclusion criteria and that were conducted in Saudi Arabia. These studies investigated different aspects of HNC, including prevalence, risk factors, biomarkers, and assessed knowledge and awareness of both public and practitioners with regard to HNC. Conclusions: This review uncovered a big gap in our epidemiological data in cancer information in general, and head and neck cancer in particular. In addition, a lack of knowledge and awareness of both the public and health care practitioners hinders the early diagnosis of disease and negatively impact the prognosis, treatment and outcome. The Ministry of Health in Saudi Arabia should develop a more systematic way and adapt policies to gather cancer information in general, and head and neck cancer in particular, from all governmental and private sectors from all over the kingdom, and develop educational programs to raise the knowledge and awareness of HNC in the country. 6. Head and neck cancer association to CIAP-2 expression due to ...  African Journals Online (AJOL) 2011-11-20 Nov 20, 2011 ... It was relevant to assess the impact of a HPV-16 (human papillomavirus-16) which is a high-risk genotype on head and neck cancers and its relation to CIAP- 7. Head and neck paragangliomas: clinical and molecular genetic classification  OpenAIRE Offergeld,Christian; Brase,Christoph; Yaremchuk,Svetlana; Mader,Irina; Rischke,Hans Christian; Gläsker,Sven; Schmid,Kurt W; Wiech,Thorsten; Preuss,Simon F; Suárez,Carlos; Kopć,Tomasz; Patocs,Attila; Wohllk,Nelson; Malekpour,Mahdi; Boedeker,Carsten C; Neumann,Hartmut PH 2019-08-31 Head and neck paragangliomas are tumors arising from specialized neural crest cells. Prominent locations are the carotid body along with the vagal, jugular, and tympanic glomus. Head and neck paragangliomas are slowly growing tumors, with some carotid body tumors being reported to exist for many years as a painless lateral mass on the neck. Symptoms depend on the specific locations. In contrast to paraganglial tumors of the adrenals, abdomen and thorax, head and neck paragangliomas seldom release catecholamines and are hence rarely vasoactive. Petrous bone, jugular, and tympanic head and neck paragangliomas may cause hearing loss. The internationally accepted clinical classifications for carotid body tumors are based on the Shamblin Class I-III stages, which correspond to postoperative permanent side effects. For petrous-bone paragangliomas in the head and neck, the Fisch classification is used. Regarding the molecular genetics, head and neck paragangliomas have been associated with nine susceptibility genes: NF1, RET, VHL, SDHA, SDHB, SDHC, SDHD, SDHAF2 (SDH5), and TMEM127. Hereditary HNPs are mostly caused by mutations of the SDHD gene, but SDHB and SDHC mutations are not uncommon in such patients. Head and neck paragangliomas are rarely associated with mutations of VHL, RET, or NF1. The research on SDHA, SDHAF2 and TMEM127 is ongoing. Multiple head and neck paragangliomas are common in patients with SDHD mutations, while malignant head and neck paraganglioma is mostly seen in patients with SDHB mutations. The treatment of choice is surgical resection. Good postoperative results can be expected in carotid body tumors of Shamblin Class I and II, whereas operations on other carotid body tumors and other head and neck paragangliomas frequently result in deficits of the cranial nerves adjacent to the tumors. Slow growth and the tendency of hereditary head and neck paragangliomas to be multifocal may justify less aggressive treatment strategies. 8. Qualidade de vida e prognóstico nos carcinomas epidermóides de cabeça e pescoço  OpenAIRE (Portuguese) Amar,Ali; Rapoport,Abrão; Franzi,Sérgio A.; Bisordi,Clarice; Lehn,Carlos N. 2019-08-31 Objetivo: avaliar um questionário para mensuração da qualidade de vida e sua relação com o prognóstico em pacientes com câncer de cabeça e pescoço. Forma de estudo: prospectivo clínico. Material e Método: estudo de 31 pacientes com carcinoma epidermóide de vias aerodigestivas superiores atendidos no Departamento de Cirurgia de Cabeça e Pescoço e Otorrinolaringologia do Hospital Heliópolis, Hosphel, São Paulo, no período de agosto de 1999 a novembro de 2000. Na avaliação da qualidade de vida empregou-se o questionário QLQ-C30 e o módulo QLQ-H&N35, ambos fornecidos pela EORTC, sendo realizada previamente ao tratamento. Foi avaliada a diferença de pontuação entre os pacientes que apresentavam doença controlada e aqueles com recidiva nos primeiros 12 meses após o tratamento. Resultados: foi observada uma diferença significativa na pontuação entre os pacientes assintomáticos e aqueles com recidiva da doença nas escalas relacionadas à fadiga, dificuldade de comer em público e qualidade de vida global (p <= 0,05). A pontuação obtida neste grupo de pacientes foi semelhante à observada em outras populações. Conclusão: a qualidade de vida prévia ao tratamento pode constituir um indicador prognóstico para os pacientes com câncer de cabeça e pescoço. 9. Polimorfismos GSTT1 e GSTM1 em indivíduos tabagistas com carcinoma espinocelular de cabeça e pescoço  OpenAIRE (Portuguese) Biselli,Joice Matos; Leal,Renata Cristina de Angelo Calsaverini; Ruiz,Mariângela Torreglosa; Goloni-Bertollo,Eny Maria; Maníglia,José Victor; Rossit,Andréa Regina Baptista; Pavarino-Bertelli,Érika Cristina 2019-08-31 A variabilidade em genes relacionados aos processos de ativação e detoxificação de carcinógenos pode interferir na suscetibilidade ao câncer. OBJETIVO: Investigar a relação entre os polimorfismos GSTT1 e GSTM1 nulos e o risco para o carcinoma espinocelular de cabeça e pescoço em indivíduos tabagistas. MATERIAL E MÉTODO: Este estudo caso-controle foi realizado na Faculdade de Medicina de São José do Rio Preto, Brasil. Foram avaliadas as freqüências dos genótipos nulos GSTT1 e GSTM1 por PCR multiplex em 60 pacientes com carcinoma espinocelular de cabeça e pescoço e 60 indivíduos sem a doença. RESULTADOS: A cavidade oral foi o sítio de tumor mais freqüente. O genótipo GSTT1 nulo foi encontrado em 33,3% dos pacientes e em 23,3% dos indivíduos controles (p=0,311). Os grupos caso e controle apresentaram freqüências do genótipo GSTM1 nulo de 35% e 48,3%, respectivamente (p=0,582). Não foram encontradas associações entre o hábito etilista e genótipos nulos GSTT1 e GSTM1 em ambos os grupos (valores de p>0,05). O gênero masculino e o hábito etilista foram prevalentes em ambos os grupos. CONCLUSÃO: Neste estudo não foi possível estabelecer uma correlação entre os genótipos nulos GSTT1 e GSTM1 e o carcinoma espinocelular de cabeça e pescoço em indivíduos tabagistas. 10. Avaliação dos parâmetros de halitose através do Oralchroma nos pacientes submetidos à radioterapia de cabeça e pescoço  OpenAIRE (Portuguese) Gustavo Maluf Dib Valerio 2019-08-31 A radioterapia de cabeça e pescoço apresenta alguns efeitos adversos orais como hipossalivação e halitose, a qual pode ser mensurada por um dispositivo, o Oralchroma, que é um cromatógrafo gasoso que permite a mensuração dos 3 principais gases do mau-hálito: Sulfidreto (HS), Metilmercaptana (MM) e Dimetilsulfeto (DMS). O objetivo deste estudo foi avaliar os parâmetros de halitose através do Oralchroma® nos pacientes submetidos à radioterapia de cabeça e pescoço quando comparado a indivíduos não irradiados pela observação das relações entre os parâmetros estudados: fluxo salivar, índice de higiene oral e quantidade de biofilme lingual (WTCI) e a halitose. Realizaram-se as halimetrias sem e com o desafio da cisteína (DC), além de avaliar a relação da hipossalivação e assialia com xerostomia e ardência bucal nos pacientes submetidos à radioterapia de cabeça e pescoço. Foram selecionados 76 pacientes, sendo dividos em um grupo com 38 submetidos à radioterapia de cabeça e pescoço e, em outro grupo, com 38 pacientes não irradiados, pareados pelo sexo e idade. Os resultados mostraram que os indivíduos não irradiados apresentaram aumento significativo dos Compostos Sulfurados Voláteis (CSVs) - HS e DMS (DC) quando comparados a indivíduos submetidos à terapia antineoplásica para tratamento de câncer de cabeça e pescoço. Observou-se também a correlação entre o aumento da saburra lingual, hipossalivação e elevação dos CSVs. A hipossalivação foi significativa nos pacientes com câncer de cabeça e pescoço, mas o índice de saburra lingual foi maior no grupo de indivíduos não irradiados. Percebeu-se que, quando há assialia, o índice de saburra lingual é inexpressivo e só altera a identificação do DMS. A hipossalivação esteve relacionada com a xerostomia nos dois grupos, mas sem relação com a ardência bucal, já a assialia apresentou relação direta com ardência bucal. Nessa pesquisa, observou-se que a irradiação de cabeça e pescoço podem contribuir para formação de CSVs, contudo, estes foram mais elevados no grupo não irradiado. Esse fato pode ser atribuído à assialia, condição clínica observada significativamente nos pacientes irradiados que contribuiu para escassa produção dos CSVs (HS e MM) e foi relevante para ausência de biofilme lingual, bem como na ardência bucal. Head and neck radiotherapy presents some oral adverse effects such as hyposalivation and halitosis, which can be measured by a device, Oralchroma, which is a gas chromatograph that allows the measurement of the 3 main gases of the bad breath: Sulfidide (HS), Methylmercaptan (MM) and Dimethylsulfide (DMS). The aim of this study was to evaluate the parameters of oral halitosis in patients submitted to head and neck radiotherapy when compared to non-irradiated individuals by observing the relationships between the studied parameters: salivary flow, oral hygiene index and lingual biofilm content (WTCI) and halitosis. Halimetry was performed with and without the challenge of cysteine (DC), besides evaluating the relationship of hyposalivation and assialia with xerostomia and oral burning in patients submitted to head and neck radiotherapy. Seventy-six patients were selected, divided into one group with 38 submitted to head and neck radiotherapy and in another group with 38 non-irradiated patients, matched by sex and age. The results showed that the non - irradiated individuals presented a significant increase of the Volatile Sulfur Compounds (CSVs) - HS and DMS (DC) when compared to individuals submitted to antineoplastic therapy for the treatment of head and neck cancer. It was also observed the correlation between the increase of the lingual saburra, hyposalivation and elevation of CSVs. Hyposalivation was significant in patients with head and neck cancer, but the lingual flap index was higher in the group of non-irradiated individuals. It was noticed that, when there is assialia, the lingual flap index is inexpressive and only changes the identification of the DMS. Hyposalivation was related to xerostomia in both groups, but unrelated to oral burning, and assialia was directly related to oral burning. In this research, it was observed that head and neck irradiation may contribute to the formation of CSVs, however, these were higher in the non-irradiated group. This fact can be attributed to assialia, a clinically observed condition in irradiated patients, which contributed to low CSV production (HS and MM) and was relevant for absence of lingual biofilm as well as oral burning. 11. Rabdomiosarcoma de cabeça e pescoço na infância  OpenAIRE (Portuguese) Neves,Beatrice Mª J.; Pontes,Paulo A. de L.; Caran,Eliana M.; Figueiredo,Claudia; Weckx,Luc L.M.; Fujita,Reginaldo R. 2019-08-31 Rabdomiosarcoma é uma neoplasia maligna originária de células mesenquimais primitivas, podendo ocorrer em qualquer lugar do corpo. É o sarcoma de partes moles mais comum na infância, e localiza-se mais freqüentemente na cabeça e pescoço. OBJETIVO: Estudar a ocorrência de RMS na cabeça e pescoço na infância, correlacionando aspectos clínicos e histopatológicos. FORMA DE ESTUDO: Clínico retrospectivo. MÉTODO: Oitenta e dois pacientes com diagnóstico de sarcomas de partes moles, atendidos no Instituto de Oncopediatria da UNIFESP-EPM de 1988 a 2002 foram incluídos neste estudo. Foram estudados os seguintes parâmetros: incidência de RMS na infância e na cabeça e pescoço, distribuição segundo sexo, faixa etária, tipo histológico, localização primária, óbito X localização, causa mortis. RESULTADOS: Neste estudo 65% dos casos de sarcomas de partes moles corresponderam à RMS; 33% dos casos de RMS localizavam-se na cabeça e pescoço; 77% dos casos de sarcoma de partes moles de cabeça e pescoço corresponderam ao RMS. A média de idade no diagnóstico foi de 7,62 anos, predominando na faixa etária dos 5 aos 9 anos (41%). Em relação ao sexo, encontramos 47% do sexo feminino e 53% do sexo masculino. Quanto ao tipo histológico, o mais comum foi o RMS embrionário correspondendo a 64,6% do total. O sítio primário mais comum foi o orbital (52,8%). Cem por cento, 50% e 33,3% dos pacientes com RMS parameníngeo, não parameníngeo e orbital, respectivamente, evoluíram para óbito. CONCLUSÃO: O RMS é o sarcoma de partes moles mais comum na infância, localizando-se preferencialmente na cabeça e pescoço. Houve predominância do sexo masculino neste estudo; idade média de 7,62 anos predominando a faixa etária dos 5 aos 9 anos. O tipo histológico predominante foi o embrionário e a localização orbital foi mais freqüente. O maior índice de óbito pertenceu aos RMS parameníngeo e o menor ao orbital. 12. Primary head and neck mucosal melanoma: Predictors of survival and a case series on sentinel node biopsy. Science.gov (United States) Prinzen, Tom; Klein, Martin; Hallermann, Christian; Wermker, Kai 2019-09-01  PubMed DOI: 10.1016/j.jcms.2019.06.012  ISSN: 1010-5182  Volume: 47  Issue: 9  Pages: 1370-1377 Keywords: Head and neck neoplasm, Malignant melanoma, Mucous membrane, Prognosis, Sentinel lymph node biopsy Head and neck mucosal melanoma (HNMM) is a rare tumor with a poor outcome. The objective of this study was to assess outcome and prognostic factors for a cohort of patients treated in a head and neck cancer center. In addition, a case series on sentinel lymph node biopsy (SLNB) was included to evaluate it as a method for staging the node-negative neck. A retrospective study design was chosen, and 50 patients who were treated from 1973 to 2015 in our institution for primary HNMM were included. The Kaplan-Meier method was used to estimate survival rates. Uni- and multivariate analyses were used to study the influence of possible risk factors on the patients' outcome. These risk factors included patient demographics, tumor characteristics, and treatment modalities. All patients were treated surgically and 50% received adjuvant treatment. The median disease specific survival (DSS) was 38 months, with a 5-year survival rate of 44%. Positive surgical margin (p = 0.004) and distant failure (p = 0.005) were associated with a worse DSS. The median disease-free survival (DFS) was 27 months, with a 5-year disease-free rate of 12%. Only tumor depth >5 mm (p = 0.002) was associated with a worse DFS. Five clinically node-negative patients received SLNB and only the two SLN-positive individuals suffered from distant failure. Radiotherapy, chemotherapy, and AJCC/UICC stage had no influence on any outcome measure. Positive surgical margin and distant failure are the only independent prognostic factors for DSS. Tumor depth can predict distant failure. SLNB may be a valuable staging tool for the node-negative neck. Copyright © 2019 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved. 13. Clear cell chondrosarcoma of the head and neck  OpenAIRE Mokhtari, Sepideh; Mirafsharieh, Abbas 2018-06-25 Clear cell chondrosarcoma is a rare variant of chondrosarcoma that mostly involves the end of long bones. However, nine cases have been reported in the head and neck: four in larynx, two in nasal septum, two in maxilla and one in the skull. These cases form the basis of this review. Head and neck cases accounts for less than 5% of Clear cell chondrosarcomas in the whole body and the larynx is the most common place. The histological findings of head and neck cases are consistent with general features of this entity in the whole body and nearly all tumors in this case series had a component of conventional chondrosarcoma. Clear cell chondrosarcoma is an intracompartmental tumor and retains "Grenz zone" just beneath the epithelium. Therefore, the overlying mucosa remained intact in all laryngeal cases. Nasal tumor caused ballooning of the septum and the maxillary lesion did not involve the oral mucosa. This tumor presents various radiographic features in the head and neck area. Chondroblastoma, chondroma, osteoblastoma, osteosarcoma and metastatic renal cell carcinoma are included in the histologic differential diagnoses. Differentiation from chondroblastic osteosarcoma is important in the maxilla. A wide resection is adequate in most cases. However, some laryngeal cases show tendency to recur. Clear cell chondrosarcoma is a slow growing tumor and this necessitates a long time follow-up of patients. Due to the extreme rarity in the head and neck, diagnosis of Clear cell chondrosarcoma in this area, must be confirmed by histochemical and immunohistochemical studies. 14. Optimization of Flip Angle at Head & Neck MR Angiography using Gadoteridol (Gadoteridol을 이용한 Head & Neck MR Angiography에서의 적정 Flip Angle)  KoreaScience (Korea) Jeong, Hyunkeun; Kim, Mingi; Song, Jaejun; Nam, Kichang; Choi, Hyunsung; Jeong, Hyundo; Kim, Hochul 2016-01-01  Journal of the Institute of Electronics and Information Engineers DOI: 10.5573/ieie.2016.53.3.151  Volume: 53  Issue: 3  Pages: 151-159 Full Text Available In this research, we tried to suggest moderate FA(Flip Angle) for CE(Contrast Enhnaced)-Head&Neck MR Angiography with Gadoteridol. For this study, we did test MR phantom and clinical study according to FA change. After that, quantitative analysis was progressed. The results of MR phantom study were as follow: RSP(Reaction Starting Point)was recorded within 300~400 mmol. MPSI(Max Peak Signal Intensity) was 2,086, 3,705, 5,109, 6,194, 7.096, 7,192 [a.u]. MPP(Max Peak Point) was shown at 30, 50, 50, 40, 50, 40 mmol. IRMPSI(Increase Rate of MPSI) was 77.6%, 37.9%, 21.2%, 14.6%, 1.4% as increasing of FA. The results of clinical study were as follow SICB(Signal Intensity of Carotid artery Bifurcation) was recorded respectively 392.5, 4165.2, 4270, 3502.2, 3263.7, 3119.6 [a.u]. ORA(Occurence Rate of Artifact) was increased as 0, 0, 20, 40, 50, 70%. According to this research, we are not only able to assure that increase of FA can be effect on H1 spin's SI(Signal Intensity) which was combined with gadolinium agent, but also be effect on artifact rate in blood vessel. In clinical field, we expect that CE-Head&Neck MR Angiography can be performed in a practical way with this research. 15. A novel CYP1A1 gene polymorphism and the risk of head and neck ...  African Journals Online (AJOL) Administrator 2011-06-14 Jun 14, 2011 ... genotype in 388 head and neck cancer patients in Pakistani population ... Key words: Cytochrome P450 1A1 gene (CYP1A1), head and neck ... 16. Immune profiles in primary squamous cell carcinoma of the head and neck. Science.gov (United States) Saloura, Vassiliki; Izumchenko, Evgeny; Zuo, Zhixiang; Bao, Riyue; Korzinkin, Michael; Ozerov, Ivan; Zhavoronkov, Alex; Sidransky, David; Bedi, Atul; Hoque, Mohammad O; Koeppen, Hartmut; Keck, Michaela K; Khattri, Arun; London, Nyall; Kotlov, Nikita; Fatima, Aiman; Vougiouklakis, Theodore; Nakamura, Yusuke; Lingen, Mark; Agrawal, Nishant; Savage, Peter A; Kron, Stephen; Kline, Justin; Kowanetz, Marcin; Seiwert, Tanguy Y 2019-09-01  PubMed DOI: 10.1016/j.oraloncology.2019.06.032  ISSN: 1368-8375  Volume: 96  Pages: 77-88 Keywords: Head and neck cancer, Immune checkpoints, T-cell inflamed phenotype In this study we describe the tumor microenvironment, the signaling pathways and genetic alterations associated with the presence or absence of CD8+ T-cell infiltration in primary squamous cell carcinoma of the head and neck (SCCHN) tumors. Two SCCHN multi-analyte cohorts were utilized, the Cancer Genome Atlas (TCGA) and the Chicago Head and Neck Genomics (CHGC) cohort. A well-established chemokine signature classified SCCHN tumors into high and low CD8+ T-cell inflamed phenotypes (TCIP-H, TCIP-L respectively). Gene set enrichment and iPANDA analyses were conducted to dissect differences in signaling pathways, somatic mutations and copy number aberrations for TCIP-H versus TCIP-L tumors, stratified by HPV status. TCIP-H SCCHN tumors were enriched in multiple immune checkpoints irrespective of HPV-status. HPV-positive tumors were enriched in markers of T-regulatory cells (Tregs) and HPV-negative tumors in protumorigenic M2 macrophages. TCIP-L SCCHN tumors were enriched for the β-catenin/WNT and Hedgehog signaling pathways, had frequent mutations in NSD1, amplifications in EGFR and YAP1, as well as CDKN2A deletions. TCIP-H SCCHN tumors were associated with the MAPK/ERK, JAK/STAT and mTOR/AKT signaling pathways, and were enriched in CASP8, EP300, EPHA2, HRAS mutations, CD274, PDCD1LG2, JAK2 amplifications. Our findings support that combinatorial immune checkpoint blockade and depletion strategies targeting Tregs in HPV-positive and M2 macrophages in HPV-negative tumors may lead to improved antitumor immune responses in patients with TCIP-H SCCHN. We highlight novel pathways and genetic events that may serve as candidate biomarkers and novel targeted therapies to enhance the efficacy of immunotherapy in SCCHN patients. Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved. 17. Paediatric head and neck cancers in Nigeria: Implications for ...  African Journals Online (AJOL) 2013-02-20 Feb 20, 2013 ... Background: The head and neck (H/N) is a common site for childhood cancers. This study examined all cases of H/N childhood cancers diagnosed in a major ... 18. Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck KoreaMed Kim, Moon JinKim, Sung MinJung, Hyun AeHong, Jung YongChang, Won JinChoi, Moon KiKim, Hye SookSun, Jong MuPark, Keunchil Ahn, Myung Ju 2019-09-01  Korean Journal of Internal Medicine DOI: 10.3904/kjim.2017.234  ISSN: 0494-4712  Volume: 34  Issue: 5 Full Text Available BACKGROUND/AIMS: We investigated the efficacy and toxicity of a weekly schedule of docetaxel and cisplatin as a first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). 19. Comparison of survival rates between patients treated with conventional radiotherapy and helical tomotherapy for head and neck cancer  KoreaScience (Korea) Kong, Moonkyoo; Hong, Seong Eon; Choi, Jinhyun; Kim, Youngkyong 2013-01-01  Radiation Oncology Journal DOI: 10.3857/roj.2013.31.1.1  Volume: 31  Issue: 1  Pages: 1-11 Full Text Available Purpose: Compared to conventional radiotherapy (RT), intensity-modulated radiotherapy (IMRT) significantly reduces the rate of treatment-induced late toxicities in head and neck cancer. However, a clear survival benefit of IMRT over conventional RT has not yet been shown. This study is among the first comparative study to compare the survival rates between conventional RT and helical tomotherapy in head and neck cancer. Materials and Methods: From January 2008 to November 2011, 37 patients received conventional RT and 30 patients received helical tomotherapy for management of head and neck cancer. We retrospectively compared the survival rates between patients treated with conventional RT and helical tomotherapy, and analyzed the prognostic factors for survival. Results: The 1- and 2-year locoregional recurrence-free survival rates were 61.2% and 58.1% for the conventional RT group, 89.3% and 80.3% for the helical tomotherapy group, respectively. The locoregional recurrence-free survival rates of the helical tomotherapy group were significantly higher than conventional RT group (p = 0.029). There were no significant differences in the overall and distant metastasis-free survival between the two groups. RT technique, tumor stage, and RT duration were significant prognostic factors for locoregional recurrence-free survival. Conclusion: This study showed the locoregional recurrence-free survival benefits of helical tomotherapy in the treatment of head and neck cancers. 20. A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer. Science.gov (United States) Brisson, Ryan J; Kochanny, Sara; Arshad, Saba; Dekker, Allison; DeSouza, Jonas A; Saloura, Vassiliki; Vokes, Everett E; Seiwert, Tanguy Y 2019-09-04  PubMed DOI: 10.1002/hed.25910  ISSN: 1043-3074 Keywords: PI3K inhibitor, advanced disease, buparlisib, cetuximab, head and neck squamous cell carcinoma, metastatic disease, recurrent disease This study assessed the maximum tolerated dose (MTD) of the PI3K inhibitor buparlisib given concurrently with cetuximab in recurrent and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Twelve patients with R/M HNSCC were enrolled. Patients were given oral buparlisib starting day 7 and daily thereafter. The dose of buparlisib was escalated in a 3 + 3 design followed by a dose expansion cohort of 6 patients. The MTD of buparlisib per protocol was 100 mg daily with cetuximab given intravenously every 14 days starting day 0. Ten patients had ≥2 previous treatment regimens (11 with prior cetuximab). There were no dose limiting toxicities observed during dose escalation. One patient achieved a partial response and 4 achieved stable disease. Based on this pilot study, buparlisib at 100 mg daily plus cetuximab proved to be well-tolerated. Patients previously treated with cetuximab monotherapy showed benefit from this combination. © 2019 Wiley Periodicals, Inc.